Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for glioblastoma

a fast-growing malignant brain tumor composed of spongioblasts

References in periodicals archive ?
A snapshot of the global therapeutic scenario for Glioblastoma Multiforme (GBM).
The findings help explain why the tumours, called glioblastomas, are so difficult to treat, said study researcher Inder Verma, a molecular biologist at The Salk Institute in California.
Intravenous pretreatment with IdUrd appeared to slow or halt the progression of cancer in at least 13, including 6 of 10 patients with glioblastoma multiforme.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III AVAglio study of Avastin([R]) (bevacizumab) plus radiation and temozolomide chemotherapy in people with newly diagnosed glioblastoma met its co-primary endpoint of a significant improvement in progression-free survival (PFS).
With this SPA in place, we think that ICT-107 is uniquely positioned in the field of immuno-oncology approaches being tested in glioblastoma.
11, 2014 /PRNewswire/ -- Novocure(TM), a commercial stage oncology company, announced today that the pre-specified interim analysis of the pivotal phase III EF-14 study, a prospective, multi-center trial of Tumor Treating Fields (TTFields) together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM), will be presented as a late breaking oral presentation at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16, in Miami, Florida.
Patients with glioblastoma survive about 15 months after diagnosis on average, so there is great need for new treatments.
More than 20% of relapsed patients being free of progression after 6 months in a controlled trial was last observed some 10 years ago when temozolomide was introduced into the care of glioblastoma patients.
The supplement is intended to provide an overview of available knowledge regarding the use of NovoTTF Therapy for the treatment of recurrent glioblastoma, as well as its development for the treatment of lung cancer
Scientists behind the research believe that understanding the problems at the molecular level might one day reveal the underlying mechanism of carcinogenesis in glioblastoma and ultimately lead to treatments or even preventative measures.
This expanded collaboration covers the development and worldwide commercialization of MDxHealth's MGMT (methylguanine-DNA methyltransferase) diagnostic test (PredictMDx(TM) for Glioblastoma), which might help to identify those glioblastoma patients who might be more likely to benefit from cilengitide-based therapies that are currently under investigation, in combination with temozolomide and radiotherapy.
Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals of 20.
According to the researchers, testing for the gene can differentiate between patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer.
Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline.